You just read:

FDA Grants Fast Track Designation to Debiopharm International's Debio 1347 for the Treatment of Patients With Unresectable or Metastatic Tumors With a Specific FGFR Gene Alteration

News provided by

Debiopharm International SA

May 08, 2018, 06:36 ET